Over The Counter Stocks

[Robertscott]

$AABB is formalizing the relationship with the developer and planning the next steps to begin creating the crypto coin.

[Value_Investor]

TXCCQ is up 62.5% today after it has Bottomed out at 0.0012! Only 33M/46M shares FIXED Tiny float/OS!

Super Undervalued now --- its Cash Value alone is $0.0161 a share v.s. it is trading at joke low price $0.00195 now! The 52-week-high $0.01 was created on 12/16/2019! Easy Quick bounce to hit its most recent high $0.01 again based on Paper Thin asks of Level2 and ridiculous low MV...




OEDVQ has already Bottomed out at $0.0012! Ready to break up current joke low 52-week-high $0.0061 with $0.01 a share Huge Cash Value and 36M/58M shares FIXED Tiny float/OS! OEDVQ is a Sought-After CH11-CLEAN shell which worth $0.0172 a share!

[Robertscott]

$TOMI loaded up on the dip. Next leg up can form now

[Robertscott]

$MEDH Wyoming annual report.
https://wyobiz.wyo.gov/Business/FilingDetails.aspx?eFNum=095005198060174083219081253009120205228211135226
Introducing New President/Director Hans Enriquez, Follow him
@The1OnlyHans
. Expect big things and great leadership!

[Robertscott]

$TOMI Latest News: http://finance.yahoo.com/q/h?s=TOMI+Headlines

[Robertscott]

$LEAS Updated Chart https://www.stockscores.com/chart.asp?TickerSymbol=LEAS&TimeRange=1300&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=830&ChartHeight=500&LogScale=None&Band=None&avgType1=SMA&movAvg1=&avgType2=SMA&movAvg2=&Indicator1=RSI&Indicator2=AccDist&Indicator3=MACD&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen ;

[Robertscott]

$SCNG Strattner Financial Group (SCNG): Asset Under Management Increased 192% in the Midst of a Global Pandemic

[Alexulf]

Lexaria has come a long way to mitigate risks.

Lexaria Bioscience (OTC: LXRP; CSE: LXX) may be a micro-cap stock, but it plays in the big leagues by signing significant and potentially lucrative deals with multi-billion-dollar businesses. Most recently, Lexaria announced entering into a research and development framework agreement with British American Tobacco Limited (NYSE: BTI) to investigate Lexaria's technology for potential use in nicotine products.

The deal is valuable, and potentially accretive, on at least two fronts. First, BTI will fund all work under the final research and development agreement. And second, as a result of these non-dilutive studies, the results can become valuable assets to Lexaria and its partners. It's a win/win scenario that showcases how the innovative and patented DehydraTECH™ technology can improve the way pharmaceutical ingredients enter the bloodstream. Moreover, this latest R&D agreement further validates the interest in DehydraTECH™ as a potential game-changing platform to meet the needs of fast-changing pharmaceutical and consumer goods sectors.

In particular, the opportunities created from this research agreement can be substantial and come well-backed by an industry giant, British American Tobacco, a 118-year-old tobacco and consumer goods business with products sold in over 11 million locations across more than 180 countries. The company is focused on building "A Better Tomorrow" by reducing its business's health impact by offering a greater choice of enjoyable and less risky products for its consumers. BTI's market cap stood at over $75 billion at the end of August.

Their mission may play directly into Lexaria's strength through the DehydraTECH™ technology. Further, the additional research and development agreements already in place with other billion-dollar companies like Altria Group (NYSE: MO), position Lexaria to create near and long-term shareholder value by identifying and exploiting opportunities born through its innovative platform.

Video Link: https://www.youtube.com/embed/oNUJeOo83EU

The Broad Applications Of DehydraTECH™

The value driver at Lexaria comes through its DehydraTECH™ platform. More than improving the way active pharmaceutical ingredients (APIs) enter the bloodstream, this platform also promotes healthier ingestion methods and increases the effectiveness of fat-soluble active molecules, which, in turn, can be a valuable factor to lowering overall dosing. Also, the technology is not one-dimensional. It can be applied to numerous ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. Thus, the opportunities can be nearly endless for its commercial applications.

An example of that reach came last month when the company received ethics board approval from a European university research hospital to conduct an exploratory clinical study using cannabidiol ("CBD" formulated together with its patented DehydraTECH™ technology. The trial will assess blood pressure reduction potential in volunteers with pre-or mild hypertension. According to Lexaria, the study is designed as a double-blinded, placebo-controlled, cross-over pilot study where 24 volunteers (12 males and 12 females, aged 45-70 years) will be randomized to receive a 300 mg dose of CBD with or without DehydraTECH™ formulation enhancement. Dosing will be in oral capsule form across two separate study visits. The primary outcome will be automated measures of blood pressure and heart rate. Secondary outcome measures will include circulating plasma concentrations of CBD and assessing key inflammatory markers associated with cardiovascular disease.

Results from this study are intended to complement its previous clinical research from 2018, as published in the peer-reviewed medical journal "Advances in Therapy." In that study, a single 90mg CBD dose of Lexaria's TurboCBD™ oral capsule provided evidence of lower blood pressure, higher blood flow to the brain, faster delivery onset of CBD into the bloodstream, and larger quantities of CBD within the blood compared to a single 90mg dose of generic CBD in healthy, normotensive volunteers. Additional findings demonstrated a significant 5% reduction in mean arterial blood pressure (MAP) when normalized to end-tidal CO2 at peak blood levels of CBD with Lexaria's TurboCBD™ compared to placebo (95% CI; p=0.016). The trial is designed to evaluate performance in a pre- and mildly hypertensive population more representative of consumers who may benefit from blood pressure control and reduction.

Lexaria expects to have results from the study during the fourth quarter of 2020, with updates provided as the data is analyzed and available. The existing annual market for blood pressure control is roughly $24 billion but many of the drugs currently in use are plagued with unwanted and sometimes dangerous side effects. There is a real opportunity for Lexaria’s patented processing of CBD to enter this market, after suitable testing and evaluation.

Milestone Achieved In Completing Altria Ventures Phase I Study

With a potential catalyst in the near-term from its CBD study, Lexaria is now working to capitalize on its previously announced milestone. That event came at the conclusion of a Phase I research and development program with Altria Ventures Inc. (NYSE: MO) to evaluate oral forms of nicotine delivery utilizing Lexaria's patented DehydraTECH™ technology. Mainly, that research and development program was initiated to assess reduced health risks of a preliminary DehydraTECH™ oral nicotine formulation relative to combusted tobacco.

The results from Phase I are encouraging. In July, study data released by Lexaria showed that the DehydraTECH™ formulation showed acceptable chemical and microbiological stability and was well-tolerated in a 7-day, repeat dose acute toxicology study in rats. Critical to the safety profile, those results showed no test-article-related effects on survival, macroscopic findings, or organ weights. There were also no test-article-related histopathological tissue findings.

Further, the formulation created no throat burn or irritation issues in an oral pouch or chew formats at standard commercial doses upon small scale sensory analysis in humans. Data also demonstrated the formation of a unique mixture of nanoparticles without creating a covalently linked, new molecular entity construct upon molecular characterization by Canada's National Research Council (NRC). Thus, the formulation is not believed to be preclusive of Premarket Tobacco Product Application ("PMTA" applicability in this respect.

Lexaria noted that after completing the Phase I study, Altria preserved its right to activate the "First Warrant Tranche Trigger," a term defined in the Warrant and Option Agreement dated as of January 15, 2019. The tranche trigger activation would initiate a staged payment to Lexaria Nicotine LLC. and enable Altria to retain its current exclusivity in the US market for Lexaria's DehydraTECH™ for oral nicotine delivery purposes.

Altria currently holds an existing minority equity stake and board representation in Lexaria Nicotine LLC. and is titled to a non-exclusive license to use DehydraTECH™ worldwide. Lexaria is expected to benefit from an earlier-defined royalty payment schedule if Altria decides to utilize the technology commercially, regardless of additional R&D results.

DehydraTECH™ Delivers Speed Of Bio-Absorption

The most notable advantages to utilizing DehydraTECH™ in orally delivered products is that it increases bio-absorption by up to 5-10x, reduces the time of onset from 1-2 hours to 10-20 minutes, and masks unwanted tastes for orally administered bioactive molecules. Those advantages substantially broaden the potential applications of the technology. Examples of molecules tested or currently under investigation using Lexaria's DehydraTECH™ include anti-viral drugs, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules.

Lexaria is also expanding its revenue-generating opportunities. The company has licensed DehydraTECH™ to multiple companies across different sectors, including Altria, where the goal would be to develop smokeless, oral-based nicotine products. Other licensees include companies that produce cannabinoid beverages, edibles, and oral products. To quickly capitalize on market opportunities, Lexaria operates a licensed in-house research laboratory and owns a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

That IP portfolio provides the time and protection needed to identify and develop new platform applications. An important and timely opportunity may come in the fight against COVID-19. Lexaria has commenced a program to investigate how the rapid and effective absorption offered by DehydraTECH™ could potentially help the best anti-viral drug candidates in treating the pandemic virus. Updates from that program may also be imminent.

New Deals, Ongoing Studies Set Stage For Strong Finish In 2020.

The stage is set to produce at least one catalyst as interim results from its ongoing CBD trial evaluating blood pressure reduction in patients with hypertension is expected by the end of the year. However, late-breaking news, similar to the British American Tobacco agreement, can come at any time. And as the value of its DehydraTECH™ platform becomes more mainstream, those events are likely to occur.

Moreover, Lexaria is already leveraging established relationships with multiple pharmaceutical, nicotine, and cannabis/CBD companies to create more effective treatments and revenue-generating opportunities. And while the BTI agreement may be one of the new partnerships, the company has stated on occasion that they are in discussions with large tobacco companies to secure additional working relationships by the end of this year. That's a plurality of opportunity.

Investors should also remember that Lexaria has filed to uplist to a more senior exchange, a move that can generate a new level of interest and exposure to investors. That filing occurred in July, making updates on that status another potential catalyst before the end of 2020. For Lexaria, and its investors, combining the sum of the parts may equate to a great opportunity, especially at current price levels.

And while no investment is without risk, Lexaria has been securing important agreements and contracts with some of the world's largest companies. Having deep-pocketed allies is always welcome.

Along with a robust and innovative drug delivery platform, those relationships may play an important factor in positioning Lexaria for near and long-term success.

Visit https://get.ceo3in60.com/lxrp/ for additional insights into Lexaria Bioscience

Buy rating and target price. (buy, target price 1.20 dollars)

https://www.marketwatch.com/investing/stock/l...testimates

[Robertscott]

$SCNG Strattner Technologies LLC also signed a contract with satellite phone manufacturer AdvanceTC Limited (OTC:ATCLF) to service and commercialize up to one million phones via the Strattner.Space platform. AdvanceTC’s android based satellite-smartphone Xplore 7 is a FCC/SIRIM certified rugged satellite-smartphone with 4G LTE, satellite messaging and emergency button device which received authorization by the United States Federal Communications Commission (FCC) in 2019.

[Robertscott]

$SCNG +17.77% at .0411 with some nice hits on the Ask this hour

[jasonbond]

Nice one on $SCNG
http://www.premarketbuzz.com/strattner-financial-group-scng-asset-under-management-increased-192-in-the-midst-of-a-global-pandemic/

[Alexulf]

LXRL Billion Dollar Shot Now; Agreement with Altria (US nr 1 Tobacco company) and now a new one with BAT (international/non-US), Lexaria is in position for a major milestone; the Non-Smoking Nicotine market!

With a setup of the 2 giant companies, Lexaria will very soon go from a minor stock, to a accepted player on Wall Street (see new Investor Relation deal) - despite difficult capital markets, Lexaria has now reached the turning point!

26% insider ownership will start pay off big time... now I guess we will have a short time window with a cheap stock. Though how long? With Uplisting coming up, revenue increasing, a big portfolio of international patents and active collaboration with Fortune 500 companies - Lexarias future looks very bright.

Today trades on 0,27 - any guess from you, what`s it worth 31 of december?

My prediction is it will be above 100% value gain, being conservative smile

As always, do your own DD, this is only my opinion. Have a nice day guys.

https://www.lexariabioscience.com/

[DealerSing]

$SCNG reported awesome news last week
https://finance.yahoo.com/news/strattner-technologies-partners-pareteum-launch-123000338.html

[Robertscott]

$SCNG's Xplore X7 is the world's first Android satellite smartphone

https://advtcxplorex7.com

[Alexulf]

MarketWatch; Lexaria Biotech Target Price 1.20 US dollars

https://www.marketwatch.com/investing/stock/lxrp/analystestimates

Appreciate visits/postings on the;

LXX.CN Lexaria-board, please mark board if you find it usefull, thx!

[Robertscott]

$GTLL on alert this week! https://www.otcmarkets.com/stock/GTLL/overview

[Robertscott]

$TOMI Announces a Formal Update on its Business Activities

https://finance.yahoo.com/news/golden-triangle-ventures-inc-announces-120000732.html

[Robertscott]

$SCNG .03825 Looking for Silver here!

[PSY]

$RXMD must read - https://dailytrendingstocks.com/progressive-care-inc-otcmktsrxmd-under-the-radar-nationwide-telehealth-player-emerges/

[Value_Investor]

PUGE is on Huge Fire today with the Lowest OS count among all the $0.0001-Bottom stocks! Only 525M shares FIXED Tiny float and 634M shares FIXED Tiny OS! Easy to hit its most recent high $0.0060 again!

This hidden gem has "ACTIVE" Nevada status which is a Good News for all the common shareholders v.s. its peer (OCLG) has "Revoked" status but it soared 16-Bagger with 1B shares! To match the Same MV with OCLG at $0.0016, PUGE will create a New 52-week-high $0.00252 v.s. at joke low $0.0003 now!

To match the same market value with its peer EVTI (with 2,952,116,907 shares Giant OS), PUGE will hit a New 52-week high $0.0247 which is 247 Times of its Bottom price!

To match the same market value with its peer VSYM (with 1,909,926,481 shares Giant OS), PUGE will hit a New 52-week high $0.0121 which is 121 Times of its Bottom price!

To match the same market value with its peer LVXI (with 3,804,973,069 shares Giant OS), PUGE will hit a New 52-week high $0.0060 which is 60 Times of its Bottom price!

In fact its recent high $0.0186 = 62 Times of its current ridiculous low price 0.0003!

So PUGE is much much much cheaper than OCLG, EVTI, VSYM, and LVXI!

[Value_Investor]

CYCC has bounced 17.65% so far! Easy Double from its New Bottom...

[Robertscott]

$LEAS new HOD .0036 is hitting!! +90%

[PSY]

$RXMD up nearly 10% on the day, breaking out!

[Robertscott]

$RXMD Progressive Care’s model is to create an interconnected system between doctors,
patients, insurances, pharmacies, and caregivers.

[Robertscott]

$RXMD Interactive Chart https://www.barchart.com/stocks/quotes/RXMD/interactive-chart

[Alexulf]

TURNAROUND IS ON FOR LEXARIA Bioscience Corp/Lexaria Corp.

(See board for NEW Investor Presentation)

Lexaria Bioscience Corp (LXX.CN)
0.375 +0.025 (+7.14%) 09/16/20 [CNSX]
QUOTE OVERVIEW for Wed, Sep 16th, 2020Alerts Watch Help
Day Low
0.365
Day High
0.375
Open 0.375
Previous Close0.350
Volume19,950
Avg Vol41,593
Stochastic %K18.89%
Weighted Alpha-60.10
5-Day Change+0.005 (+1.35%)
52-Week Range0.310 - 0.990




since 09/16/19
Most Recent Stories
Lexaria Bioscience Supports Corporate Growth Initiatives by its Licensee, Cannadips CBD by the Boldt Runners Corporation
TheNewswire.ca - Wed Sep 16, 5:25AM CDT
(via TheNewswire)



LXX.CN : 0.375 (+7.14%)
Lexaria Bioscience Announces R&D Agreement With British American Tobacco
ACCESSWIRE - Mon Aug 31, 3:02PM CDT
KELOWNA, BC / ACCESSWIRE / August 31, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered a...


LXX.CN : 0.375 (+7.14%)
Lexaria Bioscience to Present at the LD 500 Virtual Conference
ACCESSWIRE - Thu Aug 20, 6:17AM CDT
Company to discuss its Phase I R&D program with Altria Ventures Inc., for oral forms of nicotine delivery utilizing its patented DehydraTECH™ technology

LXRP : 0.2835 (+4.00%) LXX.CN : 0.375 (+7.14%)
Medical Marijuana Market 2020 Industry Size, Growth, Trends, Segments and Cost Structure Analysis Research Report 2028
AmericaNewsHour - Mon Aug 3, 7:25AM CDT
Research Nester published a report titled which delivers a detailed overview of the medical marijuana market in terms of market segmentation by end- user, by product, by application, and by region.


Lexaria Announces 2020 Annual and Special Meeting Results
TheNewswire.ca - Wed Jun 24, 5:15AM CDT
(via TheNewswire)

LXRP : 0.2835 (+4.00%) LXX.CN : 0.375 (+7.14%)
Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives New Expanded Health Canada License
TheNewswire.ca - Thu Jun 18, 5:30AM CDT
(via TheNewswire)

LXRP : 0.2835 (+4.00%) LXX.CN : 0.375 (+7.14%)
Medical Marijuana Market To Grow During 2020-28 On Account Of Increasing Adult Patients With Chronic Diseases
AmericaNewsHour - Wed Jun 17, 6:52AM CDT
Research Nester published a report titled which delivers a detailed overview of the medical marijuana market in terms of market segmentation by end- user, by product, by application, and by region.


Marijuana Market Trends, Share, Size, Growth, Supply and Manufacturers Analysis Research Report 2025
AmericaNewsHour - Wed Jun 17, 3:38AM CDT
Global Marijuana Market was valued at USD 17.2 Billion in the year 2017. Global Marijuana Market is further estimated to grow at a CAGR of 22.9% from 2019 to reach USD 88.97 Billion by the year 2025. North...

Barchart Technical Opinion LXRP Lexaria Bioscience Corp.

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

(See board for NEW UPDATED Investor Presentation)

[Alexulf]

The Billion Dollar Opportunity; The Agreement with Altria (US nr 1 Tobacco company) and now a new one with BAT (international/non-US), Lexaria is in position for a major milestone; the Non-Smoking Nicotine market!

With a setup of the 2 giant companies, Lexaria will very soon go from a minor stock, to a accepted player on Wall Street (see new Investor Relation deal) - despite difficult capital markets, Lexaria has now reached the turning point!

26% insider ownership will start pay off big time... now I guess we will have a short time window with a cheap stock. Though how long? With Uplisting coming up, revenue increasing, a big portfolio of international patents and active collaboration with Fortune 500 companies - Lexarias future looks very bright.

Today trades on 0,27 - any guess from you, what`s it worth 31 of december?

My prediction is it will be above 100% value gain, being conservative smile

As always, do your own DD, this is only my opinion. Have a nice day guys.

https://www.lexariabioscience.com/

[Robertscott]

$LEAS Keep an eye on this one https://www.strategicassetleasing.net/ ;

[Value_Investor]

OEDVQ is up 14.3% so far! This hidden gem is a CH11-CLEAN Shell with the Sought-After FIXED Tiny SS --- only 36M shares float, 58M shares OS, and 190M shares AS!

Its recent high was $0.019 v.s. its New 52-week-high is only $0.0061 now!

At Hyper Oversold status --- from $0.019 to $0.0001!

Super Undervalued now --- meager $93K Market Value now v.s. its CH11-"Q" peer ALLMQ hit $18.18M MV most recently! To match the Same MV, OEDVQ will hit $0.3119 v.s. at 99.5% Giant discount price $0.0016 now!

LOL, even a CH7-NON-CLEAN-shell peer (RCPIQ) could hit $1.01M MV which corresponds to the MV of OEDVQ at $0.0173!

OEDVQ has $0.01 per share Huge Cash Value! $0.42 per share Giant Asset Value! $0.421 per share Giant Enterprise Value!

This hidden gem has 237-Bagger Giant rally history --- from previous Bottom $0.01 to the record high $2.37!

[Robertscott]

$BTHR News: Sports Venues of Florida Announces Shadow Gaming to Start Its Premium Subscription Service September 16, 2020 08:00 ET | Source: Sports Venues of Florida, Inc. Revenue Begins November 2020 TAMPA, FL, Sept. 16, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Sports Venues of Florida, Inc., (OTCMKTS: BTHR) (“Sports Venues of Florida”, “BTHR”, or the “Company”), an emerging leader in the youth sports, family sports entertainment, and eSports markets, is excited to announce its wholly-owned subsidiary Shadow Gaming to start its premium subscription service which brings in revenues starting November 2020. Shadow Gaming was just an idea in late March 2020. Serious work began in May 2020. In just five short months Shadow Gaming has gone from concept to a revenue producing force in the eSports space. Our portal for players, organizers and leagues will be in beta testing starting the 21st of October to make sure all features will be tested before going live. Our interactive website will provide an array of different options allowing self-registration for players, organizers, and leagues to compete on all scheduled events. Each registrant will have their administration panel. The players can update their profile, see their stats and competitor’s stats scorecard in real-time so they can be reviewed before or after events. Organizers can set up their events on games that we accept based on our rules and submit them to us for approval. We are ready to be part of the exponential growth of the industry that is expected to grow to almost 140 billion by 2021. The company is working on multiple revenue streams; these revenue streams will help the company bring in much anticipated cash flow. The following four paragraphs are brief descriptions of all the revenue streams we are developing and will be online starting in November 2020. The first revenue stream is our monthly premium subscription service where players can, regardless of skill, win cash prizes and non-cash of unprecedented sizes for amateur play. The second revenue stream is Studios/Games developers; there is an average of 100 games or more released by Indie developers every week. Studios need to promote games to get them out into the player’s eyeballs. It is logical for them to use and pay for our database of players to promote their game titles. The third revenue stream is selling advertising space and time on our platform. We will monetize our website traffic with banners, Twitch Channel, YouTube, Facebook videos, sponsor by registration page ads, create a landing page for sponsors and create yearly special events by large brands. We can have multiple brands sponsor and make one large event monthly. This would potentially include companies like Coca-Cola, Red Bull, Pepsi, Frito-Lay and alike. We will be giving sponsor names to prizes like Red Bull Players Cup as an example. There is no limit to our potential. The fourth revenue stream is (EGBN) eSports Games Broadcasting Network (advertising tool). We will create a caster's dream by consolidating all streaming platforms in one place. Having. our commentary for all events in our Esports Broadcasting Channel like any live sports network. We can broadcast live events from anywhere on the planet in a centralized channel. Shadow Gaming President Luis A Arce said, “We need the shareholders and investors of Sports Venues of Florida to look at the big picture and join us in our vision to make our company a force in the esports industry.

[Value_Investor]

TWNE is up over 24.2% today! This hidden gem had already soared 75-Bagger most recently from its 52-week-low $0.0020 to current 52-week-high $0.15! It should be easy to hit the Dollar Land (only $1.586M MV at $1.00) within just a couple of days based on its 1.586M shares FIXED Super Tiny OS count! Possible 10000-Bagger Giant rally to hit $3.00 (i.e. $4.758M MV) from its All-Time-Low $0.0003 within a short period...

To match the Same MV with its peer (ADGS: from $0.0050 to $8.30), TWNE will hit $210.4034 which is over 2732.5 Times of its current ridiculous low price $0.077! At the target price every 10,000 shares of TWNE will be worthy eye-popping $2,104,034 or over $2.1M!

Both TWNE and its peer (OCLG) are CLEAN shells! OCLG hit a New high 0.0016! Buying OCLG at 0.0016 = buying TWNE at 1.01 vs at 92.4% Huge discount price 0.077 now!

[ProfitScout]

$XALL is delivering strong results from the company's multiple subsidiaries engaged in finance and business development services for a range of industries.

Xalles Holdings Reviews Q2 Achievements and 2020 Outlook

WASHINGTON, DC, Aug. 20, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ? Xalles Holdings Inc. (OTC: XALL), a fintech holding company providing technology and financial services solutions, is pleased to announce the highlights from the second quarter disclosures and outlook for the remainder of 2020. Xalles has achieved many milestones during the last quarter and has demonstrated its ability to execute against its overall roadmap.

Q2 Achievements

Xalles Holdings released its Quarterly Report and Financial Statements yesterday on August 19, 2020 for the quarter ending June 30, 2020. Despite the challenges posed by the pandemic and the limited mobility of team members to travel, the second quarter of 2020 was record-setting as Xalles recorded its second consecutive quarter of profitability.

The balance sheet recorded a significant increase in the cash balance at the end of Q2 (greater than $200,000) compared to Q1, which was driven by new loans and equity investments.

During the second quarter, Xalles completed the closing of the Intel365, Inc. acquisition on May 15, 2020, and the Argus Technology Partners, Inc. acquisition on May 31, 2020.

2020 Outlook

Xalles will continue to foster the realization of synergies between the recently acquired companies. Argus Technology Partners is committed to selling the Brick by MinervaWorks and their Managed Services offerings to its channel partners and direct prospects. Intel365 is completing the development of its new background check services which can also be distributed through the Argus sales network.

Xalles is preparing to have a cryptocurrency technology-based trading solution ready to launch before the end of the third quarter, leveraging ATN Trading’s technology platform and the one-year-old partnership Xalles has with ATN. The recent strength in cryptocurrency is extremely favorable for our outlook, given Xalles Capital’s plans to acquire cryptocurrency assets in 2020.

In the third quarter, Xalles will invite the first group of fintech company applicants to become part of the Fintech Growth Center Program. This program will provide a unique opportunity to a select group of applicants that allows them to grow their company while under Xalles’ guidance and mentoring which could prime them for continued development and potential future acquisitions.

During the third quarter, Xalles will aim to complete the closings for 2 acquisitions previously announced, namely Adaptive Metadata Solutions and 1Rivet Global. Closing these acquisitions could result in a large increase in revenues this year and in 2021, while being transformative to the company. Xalles is also in discussions with a large pipeline of acquisition candidates while it pursues continuing fundraising efforts to support those deals.

Xalles is anticipating that its Reg A public offering will be qualified by the SEC during the third quarter which will give Xalles some flexibility in its fundraising plans going into 2021. The Xalles Holdings strategy also includes a plan to Uplist to the OTCQB (Quotation Board) prior to the end of 2020.

Xalles estimates at least $4,000,000 in 2020 revenue, based on the acquisitions already completed.

About Xalles Holdings Inc. (OTC: XALL)

Xalles Holdings Inc. is a holding company that focuses on direct investments in disruptive fintech companies. The company actively seeks acquisition targets in which it can invest and accelerate growth, targeting companies with solid management teams and business models, large total attainable markets (TAM), and lucrative exit opportunities. The company places emphasis on leveraging blockchain technologies to provide industry-leading financial reconciliation and auditing solutions, which, over time, will allow for the capture of recurring revenue streams. For more information visit: http://Xalles.com

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov and in OTC Markets at www.otcmarkets.com

Investor Relations Contact:
[e-mail]
http://www.Xalles.com
202.595.1299 Office

Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[e-mail]

[Robertscott]

$ALST Announces Sales of over $100,000 of Covid-19 Rapid Antibody Tests, and other Coronavirus-Related Products

[DealerSing]

From $ALST President: "We are in discussions to acquire a revenue-producing company based in the North East US with currently only a local reach. They have a small sales force promoting to Doctors' offices, unique Health Supplements in the Diabetes and Weight Management area. These two conditions are now known to increase both the morbidity and mortality of persons infected with the Covid-19 virus. AllStar believes these unique supplements may be beneficial in the overall strategy to combat the effects of Covid-19. This acquisition is also strategic for AllStar's growth and our goal is to expand the sales of these products throughout the US and possibly other countries in the Americas," stated Dr. Daniel Bagi, President of AllStar.

[Robertscott]

$LEAS company profile on OTCMarkets
https://www.otcmarkets.com/stock/LEAS/profile

[ProfitScout]

$DFCO is getting attention now as the company financials are brought up to date highlighting recent progress with sanitizing product sales and revenue gains.

Dalrada Financial Corporation Announces 2020 Financial Results (Unaudited)

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Dalrada Financial Corp. (OTC Pink: DFCO) announces the Company's financial results for the twelve month period ending June 30, 2020 with growth of 1,602% year-over-year. Dalrada achieved $1,228,604 Total Revenues, and a 43% Gross Profit Margin for fiscal year 2020 - this is compared to prior year results of $72,155 Total Revenues in fiscal 2019. The Company will report a net loss due to increased research & development costs, capital expenditures towards production & warehousing facilities, manufacturing of finished goods, inventory and equipment purchases, and marketing of products and services. In the fourth quarter of 2020 ending June 30th, the company recorded $827,797 Total Revenues as compared to $351,324 recorded in the previous quarter ending March 31, 2020.

The increase in performance resulted from distribution and consumer sales of GlanHealth's alcohol-free sanitizing products and services, Prakat Solutions' expansion with existing customers and new U.S. opportunities in software and mobile application development services, and Dalrada Precision's addition of bespoke parts with existing customers including new customer orders. Dalrada will release audited financials in approximately three weeks from this announcement.

DALRADA HEALTH
Dalrada Health's primary focus is solving world health problems. The GlanHealth™ revolutionary line of alcohol-free sanitizing products include:

Hand Sanitizer Foam, Wipes and Spray
Advanced Sanitizing Soap
All Purpose Advanced Surface Cleaner
Antimicrobial Wound & Skin Therapy
Mold and Mildew Sanitizing & Prevention
Laundry Sanitizing & Deodorant
As stated in Dalrada's previous corporate announcement, GlanHealth feels that companies that take shortcuts are short lived – especially newcomers to the sanitizing industry. GlanHealth™ is fulfilling increased global business and consumer demand for alcohol-free sanitizing solutions. GlanHealth™ is committed to following a strategic approach to building a sustainable business model based on purity and consumer trust.

DALRADA PRECISION – Dalrada Precision is focused on the development of products that allow for design, engineering, manufacturing, and distribution on a global scale. Dalrada Precision helps realize ideas from concept and delivery to after sales service, offering unique and specific solutions. At all levels and all verticals of its operations, Dalrada Precision's mandate is the development of products that lessen the burden on engineering design, manufacturing processes, regulatory demands, cost, and distribution.

Dalrada Precision produces its precision parts in Malaysia supplying assembly parts to OEM manufacturers. Dalrada Precision's overseas production capabilities and supply chain partnerships presents a significant cost-savings to domestic components and parts sourcing.

PRAKAT SOLUTIONS – Prakat Solutions Inc. (Prakat) is a technology solutions company specializing in Test Engineering, Accessibility Engineering, Product Engineering, and Application Modernization. Prakat partners with its clients to create a transparent, value-based relationship, leveraging the extensive experience of its team to provide innovative solutions in a wide range of technology domains that enable customers to successfully attain their business goals.

A provider that is committed to empowering individuals with disabilities, the areas of focus in this line of services include assistive and adaptive technologies, testing and automation, accessibility readiness, accessibility engineering, and legal compliance of accessibility standards (W3C and other country-specific regulations such as the American Disabilities Act (ADA), British Standard 8878 (BS 8878), and the Canadian AODA).

About Dalrada Precision
A subsidiary of Dalrada Financial Corp., Dalrada Precision has been focused on solution-based engineering and the customer experience from day one. By continually delivering on its promises, the Company has created trust while building mutually-successful long-term relationships.

Dalrada Precision is a team of highly trained and committed individuals. The company takes pride in solving the unique challenges of its customers and constantly improves and enhances its machining and manufacturing capabilities, ultimately becoming a key strategic partner of many businesses. For more information, please visit www.dalradaprecision.com.

About Dalrada Health
A subsidiary of Dalrada Financial Corp., Dalrada Health is focused on solving health problems around the world. The company develops products and services that address the unmet needs of consumers due to accessibility, affordability, or availability. With operations in the U.S., Malaysia, and India, Dalrada Health can reach underserved markets through strong partnerships and the development of efficient supply chains. Dalrada Health is committed to solving universal health problems through improved methodologies resulting in products and services that benefit the global marketplace. For details, visit www.dalradahealth.com For information on GlanHealth™ visit www.glanhealth.com

About Prakat Solutions
Prakat Solutions Inc. is a technology solutions company specializing in test engineering, accessibility engineering, product engineering, and application modernization. The company partners with clients to create transparent, value-based relationships by leveraging the extensive experience of its team and by providing innovative solutions in a wide range of technology domains that ultimately enable customers to successfully attain their business goals. The Prakat work culture is based on the belief that, "we believe in what we do; we do what we love." Prakat is an ISO 9001-certified company with several Fortune 1000 customers. With its main engineering center in Bangalore, India, the company also has offices in Dallas, Texas, Denver, Colorado, and San Diego, CA. The Prakat team provides end-to-end product engineering services across various domains including banking and financial services, telecom, retail, healthcare, manufacturing, legal, and IT infrastructure. For more information, please visit http://www.prakat.com.

About Dalrada (DFCO)
Dalrada Financial Corp. (OTC Pink: DFCO) solves real-world problems by producing innovation-focused and technologically-centered solutions on a global level. Delivering next-generation manufacturing, engineering, and healthcare products and services designed to propel growth, Dalrada is a team of industry experts and an organization built upon a strong foundation of financial capital. The Company and its subsidiaries are positioned for stable long-term growth through intelligent market research, sound business acumen, and established operational infrastructure. For more information, visit http://www.dalrada.com or call 1-858-283-1253.

Disclaimer
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K.

[Alexulf]

LXRP PRESSRELEASE TODAY; possibly catalyst for the stock.

https://www.marketwatch.com/press-release/lexaria-bioscience-inks-rd-framework-deal-with-british-american-tobacco-dehydratechtm-platform-provides-growth-tailwind-into-q4-2020-09-14

16-20 july the stock had a 100% run, will we see something similar again soon?

[Robertscott]

$NAFS Voycare Welcomes Fudan University's Xuan Zhou to Board of Directors https://finance.yahoo.com/news/voycare-welcomes-fudan-universitys-xuan-124500323.html

[Robertscott]

$ALST Allstar Health Brand (ALST)
0.1325 + 0.015 (12.77%)
Volume: 6,100 @09/14/20 9:32:48 AM EDT

[GameMaster]

$NAFS News: Voycare Enters into MOU with Salesforce.com Backed and Official NASA ISS Video Conferencing Platform VSee Lab Inc. to Power its Chinese language Women's Digital Health Platform

https://www.accesswire.com/604504/Voycare-Enters-into-MOU-with-Salesforcecom-Backed-and-Official-NASA-ISS-Video-Conferencing-Platform-VSee-Lab-Inc-to-Power-its-Chinese-language-Womens-Digital-Health-Platform

[Value_Investor]

DESTQ (a NASDAQ Big-Business-Online-Retail stock just ten months ago) is up 5.24% today! This hidden gem is heading back onto inevitable Dime Land now...

Its most recent high was $0.239 v.s. it is trading at joke low $0.0201 currently!

DESTQ has Giant Positive Liquidation Value ($9.00 a share Post-CH11) and Huge Positive Book Value $1.51 a share Pre-CH11!

DESTQ is Super Undervalued now --- its total current Net Asset is 1695 Times of its ridiculous low Market Value at the Bottom! The Cash Value alone is over $0.4271 per share!

DESTQ is also Hyper Oversold --- 98.98% Giant price crash from the previous Bottom $0.5 (pre-CH11-rumor) to the New Bottom $0.0051!

The current 52-week-high is $0.9333!

You're welcome, bro.! DESTQ is the Cheapest and Mostly-Valuable CH11 stock based on its Huge Cash Value and Giant Liquidation Value plus the FIXED Sought-After Super Tiny SS --- 9M/14M/20M shares float/OS/AS!

[Robertscott]

$NAFS ~ Check out the new Investor Presentation

https://s3.amazonaws.com/content.otcmarkets.com/media/273768954/ynOAYqPVLHRwOOD/doc.pdf

[Value_Investor]

WPUR is up 28.6% so far! Only 246.7M shares FIXED Small OS! At joke low 0.0007 now v.s. its most recent high was 0.0020!

To match the same market value with its peer EVTI, WPUR will hit a New 52-week high 0.0636 which is 90.86 Times of its current ridiculous low price 0.0007!

To match the same market value with its peer OCLG, WPUR will hit a New 52-week high 0.0065 which is 9.29 Times of its current ridiculous low price 0.0079!

WPUR is much much much cheaper than EVTI and OCLG!

[Robertscott]

$SGTM in February 2020 acquired 35-year-old industry leader and innovator
Mulch Manufacturing, Inc., an Ohio corporation.

[Robertscott]

$SGTM The strategic partnership with a national waste disposal company has provided millions of dollars in cost savings and years of time that would otherwise have been incurred if the Company had needed to secure the required locations and permits that the partnership provided. This partnership represents significant potential expansion opportunity for SGTM.

[Robertscott]

$SGTM has chosen as its new headquarters the Mulch Manufacturing 100,000-square-foot building in Jacksonville, Florida. The facility comprises centralized operations of Mulch Manufacturing, Inc. and National Storm Recovery, LLC, and has ample room to expand as the needed. Permitting is near completion to open wood recycling yard at the Lane Avenue facility in Jacksonville, Florida.

[Value_Investor]

NSPR has Great News today --- see the link below!

New high $0.55 so far! It should hit $0.66 as soon as today since its most recent high was $0.80...

https://ih.advfn.com/stock-market/AMEX/inspiremd-NSPR/stock-news/83214073/current-report-filing-8-k

[Alexulf]

How To Make Money: Cardiol Therapeutics CBD on TSX (CRDL) and OTCQX: (CRTPF)

[Value_Investor]

TBLT has bounced 11.922% so far --- from its New bottom 0.64 to 0.7163!



TWNE just created a New 52-week-high 0.15 a couple of days ago! At an Huge discount 0.065 now!



DESTQ has over $0.4271 a share Giant Cash Value and $9.00 a share Giant Liquidation Value v.s. at ridiculous low $0.0219 PPS now!



PUGE has Bottomed out at the New basement price 0.0002! At 0.0003 x 0.0004 now. Its peer (OCLG) had already exploded to 0.0016 from 0.00001 (which is 90% below 0.0001)! Tomatch the Same MV, PUGE will create a New 52-week high 0.0020!

[ProfitScout]

$SNWR Intercept Music, a Sanwire Subsidiary, Announces Two Milestones and Provides Revenue Model of Its Intercept PLUS Label Services Program
News Link:
https://finance.yahoo.com/news/intercept-music-sanwire-subsidiary-announces-143000304.html